<DOC>
	<DOCNO>NCT00308048</DOCNO>
	<brief_summary>Patients HCV genotype 2 3 infection rapid virological response treatment randomise either 14 24 week HCV treatment . Our hypothesis important difference effect two treatment effect .</brief_summary>
	<brief_title>14 vs 24 Weeks HCV Treatment Genotype 2/3 Patients With Rapid Virological Response</brief_title>
	<detailed_description>Patients HCV genotype 2 3 infection currently recommend 6 month treatment pegylated interferon alfa ( 2a 2b ) ribavirin.Approximately 80 % obtain sustained virological response ( HCV RNA undetectable 6 month treatment ) approach . However , treatment associate many sometimes serious side effect . In addition , treatment costly also econimical term . Increasing treatment duration beyond 6 month increase response rate . Shorter treatment assess small trial , result encourage . In randomised , open label , multicenter phase 3 trial acitive control patient treat pegylated interferon alfa 2a ( PegIntron ( R ) , Schering Plough NJ ) ( 1,5 mcg/kg ) ribavirin ( Rebetol ( R ) , Schering Plough , NJ ) ( 800-1400mg base weight ) 4 week . Those HCV RNA negative week 4 ( &lt; 50 IU ; Cobas Amplicor Monitor Test , Roche Diagnostic ) define rapid virological responder randomise either additional 10 20 week combination treatment . Patients HCV RNA positive treat 20 week . The endpoint sustain virological response define undetectable HCV RNA 24 week end treatment . Our hypothesis important difference effect two group . This non-inferiority trial . The small difference consider clinically important 10 % . Thus state `` non-inferiority '' 95 % confidence interval observe difference group shall overlap 10 % . Both intention treat per protocol analysis publish . Conclusion conservative base analysis detect big difference .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>HCV RNA positive Genotype 2 3 Treatment naive Raised ALT Active substance abuse Poorly control psychiatric disease Decompensated cirrhosis HBsAg positive AntiHIV positive Suffering significant concurrent medical condition include chronic liver disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Interferon</keyword>
	<keyword>Pegylated interferon</keyword>
	<keyword>Pegylated interferon alfa 2b</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>Rapid virological response</keyword>
	<keyword>Short treatment</keyword>
	<keyword>14 week treatment</keyword>
	<keyword>health relate quality life</keyword>
	<keyword>sick leave</keyword>
	<keyword>Injecting drug use</keyword>
</DOC>